HCW Biologics received full payment of a $7.0 million upfront license fee from Beijing Trimmune Biotech for the development and commercialization of HCW. The cash inflow provides immediate non-dilutive funding to the clinical-stage immunotherapy developer and signals commercial interest in the program.
HCW Biologics received full payment of a $7.0 million upfront license fee from Beijing Trimmune Biotech for the development and commercialization of HCW. The cash inflow provides immediate non-dilutive funding to the clinical-stage immunotherapy developer and signals commercial interest in the program.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
